Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Dr Martens shares up as guidance held despite Q3 sales slump

(Sharecast News) - Shares in Dr Martens surged on Thursday as investors breathed a sigh of relief that the UK bootmaker held full year guidance after third-quarter revenues slumped by a fifth, driven by a poor performance in the US and from its wholesale channel. The company, which issued a profits warning in November, posted revenues of £267m for the last three months of 2023, down 21%. Wholesale orders plunged by 46%.

"Trading in the quarter was volatile and we saw a softer December in line with trends across the industry. Whilst the consumer environment remains challenging, we are taking action to continue to grow our iconic brand and invest in our business. We remain confident in our product pipeline for autumn/winter 2024 and beyond," said chief executive Kenny Wilson.

"The guidance for full year constant-currency revenue decline of high single-digit percentage year-on-year, remains unchanged. All other guidance for 2024 also remains unchanged."

Total revenues dropped by 31% in the US, compared with 15% in Europe, the Middle East and Africa, and by 8% in Asia.

Dr Martens added that the stronger pound since the end of the first half would result in a £5m forex headwind if current exchange rates persist, along with a non-cash balance sheet translation charge of approximately £5m.

"It's been a long time since we've seen Dr Martens' shares rise on a trading update but it has finally happened. While the headline figures look miserable, the positive market reaction is down to Dr Martens maintaining previous guidance rather than having to rachet it down once again," said AJ Bell investment director Russ Mould.

"Investors are breathing a sigh of relief although the company still has considerable issues to resolve."

"It's starting to look like Dr Martens is the latest in a long line of British companies which have failed to break through in the US. The bootmaker is not giving up and has a new Americas leadership team in place to fine-tune marketing strategy and e-commerce capabilities.

"An uncertain economic backdrop does not make for ideal trading conditions, particularly if people are still watching their pennies and pulling back from buying bigger ticket items. Dr Martens' boots may be iconic but they also don't come cheap."

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

Celadon inks partnership with Denmark's Valeos
(Sharecast News) - Celadon Pharmaceuticals announced a strategic collaboration with Danish pharmaceutical company Valeos Pharma on Wednesday, to accelerate the production and supply of high-THC medical cannabis across Europe.
Microlise signs three new contracts
(Sharecast News) - Microlise Group announced the signing of new and expanded contracts with Goldstar Heathrow, One Stop, and Romac on Wednesday, totaling over £2m in value.
Synergia updates Cambay Field work programme
(Sharecast News) - Synergia Energy updated the market on the planned work programme for the Cambay Field production sharing contract (PSC) in Gujarat, India on Wednesday.
Manchester United full-year losses widen
(Sharecast News) - Manchester United reported a net loss of £113.2m for the year ended 30 June on Wednesday, although the football club maintained that it was in compliance with both the Premier League's Profitability and Sustainability Rules (PSR) and UEFA's Financial Fair Play regulations.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.